STOCK TITAN

Euclidean Capital reports 2.6M shares in PMVP (PMVP)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

PMV Pharmaceuticals, Inc. Amendment No. 4 to a Schedule 13G/A reports beneficial ownership stakes held by Euclidean Capital and affiliated reporting persons. Euclidean Capital LLC and affiliated individuals/entities report 2,627,643 shares (representing 4.9%) of Common Stock.

The filing shows additional reported holdings: Greenland NFP B Ltd. 1,300,818 shares (2.4%), Greenland A LLC 346,884 shares (0.7%), and Symmetry Group Ltd. 247,203 shares (0.5%). The percentages are calculated using 53,331,766 shares outstanding as of May 12, 2026, as reported in the issuer's Form 10-Q.

Positive

  • None.

Negative

  • None.

Insights

Large holder reports sub-5% stake; positions are disclosed as shared voting/dispositive power.

The cover pages show Euclidean Capital LLC and affiliated reporting persons hold 2,627,643 shares with shared voting and dispositive power. The filing is labeled an Amendment No. 4 to a Schedule 13G/A and formally reports percentages based on May 12, 2026.

Cash-flow treatment and any planned dispositions are not stated; subsequent filings would show trading activity if holders change positions.

Disclosure aligns with passive-investor reporting thresholds under Schedule 13G; multiple entities are listed separately.

The filing lists multiple related Reporting Persons (Euclidean Capital, Mrs. Simons, Mr. Chhabra, Greenland entities, Symmetry Group) and quantifies shared voting/dispositive power per cover rows. Ownership percentages use the issuer's reported outstanding share count of 53,331,766 as the denominator.

Filing execution is certified by signatures dated 05/15/2026; no change-of-control or transaction consideration is disclosed.

Outstanding shares 53,331,766 shares as of May 12, 2026
Euclidean beneficial ownership 2,627,643 shares reported on Amendment No. 4 to Schedule 13G/A
Euclidean ownership percent 4.9% calculated using 53,331,766 shares outstanding as of May 12, 2026
Greenland NFP B Ltd. holding 1,300,818 shares cover page reported amount
Greenland A LLC holding 346,884 shares cover page reported amount
Symmetry Group Ltd. holding 247,203 shares cover page reported amount
Schedule 13G/A regulatory
"Amendment No. 4 to a Schedule 13G/A reports beneficial ownership."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Shared Dispositive Power financial
"Row 8 shows Shared Dispositive Power 2,627,643.00 for Euclidean Capital."
Beneficially owned regulatory
"Item 4(a) states the amount beneficially owned is set forth in row 9 of the cover pages."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.





69353Y103

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Euclidean Capital LLC
Signature:/s/ Joseph Cosmai
Name/Title:Manager
Date:05/15/2026
Marilyn H. Simons
Signature:/s/ Joseph Cosmai
Name/Title:Attorney-in-Fact
Date:05/15/2026
Ashvin B. Chhabra
Signature:/s/ Joseph Cosmai
Name/Title:Attorney-in-Fact
Date:05/15/2026
Greenland NFP B Ltd.
Signature:/s/ Joseph Cosmai
Name/Title:Manager of Euclidean Capital LLC, its Manager
Date:05/15/2026
Greenland NFP LLC
Signature:/s/ Joseph Cosmai
Name/Title:Manager of Euclidean Capital LLC, its Manager
Date:05/15/2026
Greenland A LLC
Signature:/s/ Joseph Cosmai
Name/Title:Manager of Euclidean Capital LLC, its Manager
Date:05/15/2026
Symmetry Group Ltd.
Signature:/s/ Joseph Cosmai
Name/Title:Vice President & Treasurer
Date:05/15/2026

FAQ

What stake does Euclidean Capital report in PMVP?

Euclidean Capital and affiliated reporting persons report 2,627,643 shares, representing 4.9% of Common Stock. The percentage is calculated using 53,331,766 shares outstanding as of May 12, 2026, per the issuer's Form 10-Q.

Does the filing show who has voting power for PMVP shares?

Yes. The cover rows report voting and dispositive powers as shared rather than sole—Euclidean and affiliates show shared voting and shared dispositive power over 2,627,643 shares, consistent with joint reporting arrangements.

How many shares outstanding does PMVP report for percentage calculations?

The filing uses 53,331,766 shares outstanding as of May 12, 2026 to calculate ownership percentages. That outstanding count is cited from the issuer's Form 10-Q filed on May 12, 2026.

Does the Schedule 13G/A state any planned sales or purchases of PMVP shares?

No. The amendment reports current beneficial ownership amounts and voting/dispositive powers but does not disclose any planned purchases or dispositions. The filing provides ownership counts and signature certifications dated 05/15/2026.